ALEC earnings analysis
What we found in ALEC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Alector's Q1 2026 10-Q report indicates a significant decline in collaboration revenue, dropping to $1.0 million compared to $3.6 million in Q1 2025, with net losses narrowing from $40.5 million to $22.9 million. The company has successfully reduced operating expenses but continues to face extensive liquidity risks and challenges in its clinical trials, particularly after GSK's discontinuation of pivotal trials. Management expects their cash reserves of $206.5 million will sustain operations through at least 2027.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Declines
- Collaboration revenue was just $1.0 million in Q1 2026, down from $3.6 million in Q1 2025.
- Improved EPS
- Loss per share improved to $0.21 in Q1 2026 from $0.41 a year earlier.
- Reduced Operating Expenses
- Total operating expenses decreased by approximately $22.4 million from Q1 2025 to Q1 2026.
- Significant Cash Reserves
- Alector reported cash reserves of $206.5 million, projected to last at least until 2027.
- Focus on Cost Management
- Management's commitments to workforce reductions aim to align with strategic priorities and maintain liquidity.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Dependency on Collaborative Revenue
- Revenue relies heavily on collaborations like GSK; discontinuations of projects could jeopardize financial stability.
- High Cash Burn Rate
- The company reported cash used in operating activities of $49.8 million in Q1 2026, raising liquidity concerns.
- Clinical Trial Risks
- Significant adverse events have led to discontinuations of trials for key programs, such as nivisnebart and latozinemab.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.21
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-K · February 25, 2026
- Alector positions itself as a clinical‑stage neuroscience company centered on its proprietary Alector Brain Carrier (ABC) BBB platform and a genetically‑validated pipeline (notably nivisnebart). The company completed…
- 10-Q · August 7, 2025
- Alector reported collaboration revenue of $7,874,000 for Q2 2025, down versus $15,083,000 in Q2 2024, while net loss narrowed to $(30,524,000) (net loss per share $0.30) from $(38,676,000) (net loss per share $0.40) a…
- 10-Q · May 8, 2025
- Alector reported collaboration revenue of $3.674M for Q1 2025 (down from $15.893M in Q1 2024) and a net loss of $40.471M (EPS -$0.41). Operating expenses declined to $48.369M vs $59.601M a year ago, but the company…
- 10-K · February 26, 2025
- Alector positions itself as a late-stage neuroscience company focused on genetically validated targets and its proprietary Alector Brain Carrier (ABC) blood-brain barrier technology. The company completed enrollment in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ALEC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever